NCT01966549 - A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

187

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

CNTO 6785

CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.

DRUG

Placebo

Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.

Trial Locations (44)

Unknown

Brno

Jindřichův Hradec

Karlovy Vary

Mělník

Prague

Praha 5 - Radotin

Strakonice

Berlin

Dresden

Frankfurt

Großhansdorf

Hanover

Koblenz

Magdeburg

Rüdersdorf

Balassagyarmat

Budapest

Farkasgyepü

Komárom

Létavértes

Mohács

Nagykanizsa

Zalaegerszeg-P Zva N/A

Batu Caves

Kota Bharu

Kuala Lumpur

Krakow

Lodz

Poznan

Wroclaw

Barnaul

Kemerovo

Novosibirsk

Saint Petersberg

Saint Petersburg

Saint-Petersberg

Saratov

Yaroslavl

Yekaterinburg

Seoul

Suwon

Wŏnju

New Taipei City

Taipei

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY